Yes, large B-cell lymphoma is a type of non-Hodgkin lymphoma. More specifically, diffuse large B-cell lymphoma (DLBCL) is the single most common form of non-Hodgkin lymphoma, accounting for roughly one in three cases. It originates in B-cells, a type of white blood cell that normally helps your body fight infections, and it belongs to the “aggressive” category of lymphomas, meaning it grows quickly but also tends to respond well to treatment.
How DLBCL Fits Within Non-Hodgkin Lymphoma
Lymphomas are cancers of the lymphatic system, and they split into two broad families: Hodgkin lymphoma and non-Hodgkin lymphoma. The key difference comes down to the specific type of abnormal cell involved. Hodgkin lymphoma contains distinctive giant cells visible under a microscope, while non-Hodgkin lymphoma does not. Within non-Hodgkin lymphoma, there are dozens of subtypes, and DLBCL is by far the largest single category.
Non-Hodgkin lymphomas are further organized by whether they start in B-cells or T-cells, and by how quickly they grow. DLBCL is a B-cell lymphoma classified as aggressive (fast-growing), which distinguishes it from slower-growing “indolent” types like follicular lymphoma. The word “diffuse” means the cancer cells spread throughout the affected tissue rather than clustering in distinct nodules, and “large” refers to the size of the individual cancer cells when viewed under a microscope.
Molecular Subtypes and Why They Matter
Not all DLBCL behaves the same way. Gene-expression studies have identified at least three molecular subtypes: germinal center B-cell (GCB), activated B-cell (ABC), and primary mediastinal B-cell lymphoma. These subtypes arise through different genetic pathways and carry meaningfully different prognoses. GCB DLBCL develops from B-cells in the part of a lymph node where immune cells normally mature, while ABC DLBCL appears to come from B-cells at a later stage of development that get stuck during their transformation into antibody-producing cells.
Patients with these subtypes have significantly different survival rates after chemotherapy. ABC DLBCL generally carries a worse outlook than GCB DLBCL. When pathologists analyze a biopsy, they use a combination of protein markers and genetic testing to determine which subtype is present, because this information helps guide treatment decisions.
Common Symptoms
DLBCL typically shows up as a fast-growing mass, most often in the neck or abdomen. You might notice painless swelling in the neck, armpit, or groin, which reflects enlarged lymph nodes. Three classic warning signs, sometimes called “B-symptoms,” often accompany the disease: unexplained fevers, drenching night sweats, and unintentional weight loss. Fatigue is also common.
DLBCL can affect more than just lymph nodes. It sometimes develops in the gastrointestinal tract, central nervous system, bones, or skin. When it arises outside the lymph nodes, doctors refer to it as “extranodal” disease. The disease typically affects older adults, though it can occur at any age.
How It’s Diagnosed
Diagnosis requires a biopsy, usually a core needle biopsy of an enlarged lymph node or mass. Under the microscope, pathologists look for sheets of large abnormal lymphoid cells. They then run a panel of tests to confirm the cells are B-cells, checking for a protein called CD20 on the cell surface. Additional markers help classify the molecular subtype.
The current World Health Organization classification system uses the term “DLBCL, not otherwise specified” (DLBCL-NOS) as a diagnosis of exclusion, meaning pathologists must first rule out other aggressive B-cell lymphomas with specific genetic signatures. Comprehensive testing, including genetic and viral evaluations, is essential for accurate classification because several related conditions can look similar but require different treatment approaches.
Staging and Survival Rates
DLBCL is staged using the Ann Arbor system, which ranges from Stage I (confined to a single region) through Stage IV (widespread involvement). Five-year relative survival rates from the National Cancer Institute’s SEER database (2016 to 2022 data) break down by stage:
- Stage I: 79.9%
- Stage II: 76.0%
- Stage III: 67.5%
- Stage IV: 56.3%
These numbers reflect averages across all patients and all molecular subtypes. An individual’s outlook depends on factors like age, overall health, molecular subtype, and how the cancer responds to initial treatment.
Standard Treatment
The backbone of DLBCL treatment is a combination regimen called R-CHOP, which pairs a targeted antibody therapy (rituximab) with three chemotherapy drugs (cyclophosphamide, doxorubicin, and vincristine) plus a steroid (prednisone). Rituximab specifically targets the CD20 protein on B-cells, and its addition to chemotherapy was one of the most significant advances in lymphoma treatment. R-CHOP is typically given in cycles spaced several weeks apart, with the exact number of cycles depending on the stage and how the disease responds.
Because DLBCL is aggressive, treatment usually begins soon after diagnosis. The good news is that aggressive lymphomas are often more responsive to chemotherapy than slow-growing types. A substantial portion of patients achieve complete remission with first-line treatment.
When Initial Treatment Doesn’t Work
For patients whose DLBCL comes back after treatment or doesn’t respond to R-CHOP, a newer class of therapy called CAR-T cell therapy has changed the landscape. This approach involves collecting your own immune cells, genetically engineering them in a lab to recognize and attack lymphoma cells, and then infusing them back into your body.
Three CAR-T products have been approved for large B-cell lymphoma, with the first arriving in 2017 and the most recent in 2021. Initially reserved for patients who had already failed two or more treatments, CAR-T therapy is now recommended as a second-line option for high-risk DLBCL that relapses or resists initial treatment, based on clinical trials showing it outperformed the older approach of salvage chemotherapy followed by stem cell transplant.
Eligibility for CAR-T therapy can be complicated for older patients, who may have other health conditions that increase the risk of side effects. Specialized assessments help oncology teams determine whether the benefits outweigh the risks for each individual.